Recent tensions between the United States and China have extended into the biotech and pharmaceutical sectors, sparking bipartisan calls for increased regulatory scrutiny. At the heart of the matter: clinical trials conducted by U.S. pharmaceutical companies in collaboration with Chinese
Eli Lilly's groundbreaking medication, tirzepatide, also known as Mounjaro and Zepbound, has demonstrated remarkable success in reducing the risk of Type 2 diabetes and promoting weight loss. The results from the extensive Phase 3 trial, named SURMOUNT-1, have sparked significant interest and
In an impressive turn of events, the U.S. Food and Drug Administration (FDA) has lifted the partial hold on BioNTech and MediLink Therapeutics' clinical trial for their groundbreaking Antibody-Drug Conjugate (ADC) candidate BNT326/YL202. Originally put on hold due to serious safety concerns,
In a significant breakthrough for cancer treatment options, Tanvex BioPharma USA, Inc. ("Tanvex" or the "Company") announced that the FDA has approved their biosimilar product NYPOZI (filgrastim-txid) and accepted their Biologics License Application (BLA) for TX-05. These
Accenture, a global professional services company renowned for its expertise in strategy, consulting, and technology, has made a strategic investment in Earli Inc., a biotechnology firm dedicated to revolutionary early cancer detection. This strategic move is managed through Accenture Ventures and
AN2 Therapeutics, a prominent biopharmaceutical company, has announced a major restructuring of its operations following an unexpected clinical trial outcome. This decision marks a significant strategic pivot from their previous research initiatives and has substantial implications for the
